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Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is a leading pathogen of healthcare-associated
infections in intensive care units (ICUs). Prior studies have shown that decolonization of MRSA carriers is an effective
method to reduce MRSA infections in ICU patients. However, there is currently a lack of data on its effect on mortality
and medical cost.
Methods: Using a quasi-experimental, interrupted time-series design with re-introduction of intervention, we evaluated
the impact of active screening and decolonization on MRSA infections, mortality and medical costs in the surgical ICU
of a university hospital in Taiwan. Regression models were used to adjust for effects of confounding variables.
Results: MRSA infection rate decreased from 3.58 (baseline) to 0.42‰ (intervention period) (P <0.05), re-surged to
2.21‰ (interruption period) and decreased to 0.18‰ (re-introduction of intervention period) (P <0.05). Patients
admitted to the surgical ICU during the intervention periods had a lower in-hospital mortality (13.5% (155 out of 1,147)
versus 16.6% (203 out of 1,226), P = 0.038). After adjusting for effects of confounding variables, the active screening and
decolonization program was independently associated with a decrease in in-hospital MRSA infections (adjusted odds
ratio: 0.3; 95% CI: 0.1 to 0.8) and 90-day mortality (adjusted hazard ratio: 0.8; 95% CI: 0.7 to 0.99). Cost analysis showed
that $22 medical costs can be saved for every $1 spent on the intervention.
Conclusions: Active screening for MRSA and decolonization in ICU settings is associated with a decrease in MRSA
infections, mortality and medical cost.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA), first
reported from England in 1961, is a leading pathogen of
nosocomial infections in intensive care units (ICUs)
[1,2]. In recent years, reduced susceptibility to vanco-
mycin has made MRSA more difficult to treat than
before [3,4]. Patients who have healthcare-associated* Correspondence: fangct@ntu.edu.tw; hsporen@ntu.edu.tw
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risk and prolonged hospital stay, resulting in increased
medical costs, compared with patients who do not have
HA-MRSA infections [5].
A significant proportion of MRSA infections are
endogenous and are caused by the same strain that
colonizes the nasal mucosa [6,7]. Observational studies
[8-12] and the REDUCE MRSA trial [13] have consistently
shown that decolonization of ICU patients, using intra-
nasal mupirocin and chlorhexidine body-washing, can
reduce MRSA infection rates. Decolonization directly
reduces endogenous infections in carriers, and indirectly. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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whether the ultimate goals of infection control, that is, the
reduction of medical cost and mortality, can be achieved by
these sorts of interventions remains unsettled, as previous
studies did not look for these outcomes [14,15].
In Taiwan, MRSA was first reported in the 1980s [16].
The proportion of MRSA among all S. aureus isolates that
cause infections in ICUs has increased to approximately
80% [16,17]. In our hospital, MRSA infection rates in the
ICU remained high, despite efforts on contact isolation and
decolonization of patients with clinical MRSA infections.
To control the problem, a routine active MRSA screening
and decolonization program was implemented in the
surgical ICU (SICU), which led to a rapid drop in MRSA
infection rate. The program was temporarily suspended
between May 2008 and August 2009, owing to a lack of
financial support, followed by a resurge in MRSA infection
rate. The program was then restarted in September 2009,
and the MRSA infection rate rapidly decreased again.
Using a quasi-experimental study design, we sought to
evaluate the impact of active screening and decolonization
of ICU patients, including both direct and indirect
protective effect, on the incidence of MRSA infections,
mortality and medical costs.
Methods
Setting
This study was conducted in the SICU of Taipei Medical
University Hospital (TMUH), a tertiary care, university-
affiliated teaching hospital in northern Taiwan. TMUH
has a 702-bed capacity. The SICU has 18 beds (all are
single bed rooms).
Ethical statement
The institutional review board (IRB) of TMUH approved
the study protocol (protocol number: TMUH-05-11-04).
The IRB approved the waiver of informed consent (see
Additional file 1).
Study design
This was a quasi-experimental, interrupted time-series
study [18]. Regression models were used to adjust for the
effects of confounding variables, including hospital-level
infection-control practices (hand hygiene and bundle care)
and patient-level risk factors (invasive procedures and
severity of underlying diseases). Data on MRSA infection
rate, mortality and medical cost were retrospectively
obtained from computer databases.
The study period was divided into four stages. In
period one (baseline, between January and September
2007), contact precautions, eradication and environ-
mental disinfection at discharge were performed only
for those patients with positive clinical cultures for
MRSA. In period two (intervention period), routineactive screening and decolonization (supported by a
research grant from the hospital) was initiated and
lasted between October 2007 and April 2008. The inter-
vention was halted in period three (interruption period,
between May 2008 and August 2009) owing to a lack of
research grants. After a resurgence in the SICU MRSA
infection rates during period three prompted the hospital
leadership to provide financial support for the active
screening and decolonization program, the intervention
was resumed in period four (reintroduction period,
between September 2009 and September 2010) (Figure 1).
We compared the HA-MRSA infection rates and
mortality rates [5] of all patients admitted during the
intervention periods (period two and period four) to those
of patients admitted during the non-intervention periods
(period one and period three), after adjusting for effects of
other variables that may influence the outcomes.
Study interventions
The intervention consisted of active surveillance cultures
that were immediately taken from the anterior nares of the
patients at the time of admission to the SICU to identify
asymptomatic MRSA carriers. Extra-nasal cultures were
not obtained. Before culture results became available,
patients were put in a single-bed room and standard
precautions were applied. If nasal swab cultures were
positive, MRSA was eradicated from the nares by the
application of mupirocin ointment (GlaxoSmithKline, GSK,
Crawley, United Kingdom) three times per day for five days,
and from the skin by the application of 4% chlorhexidine
gluconate (Panion & BF Biotech Incorporation, Taoyuan,
Taiwan) once per day for five days; contact precautions
were also taken. Patients were screened for MRSA carriage
only at their admission, rather than regularly during their
stay in ICU.
Microbiological procedures
During the intervention periods (period two and period
four), the nasal swab was plated on blood agar plates, which
were incubated at 35°C with 5% CO2 in ambient air, and
were checked for the presence of S. aureus after 16 to
18 hours of incubation. To shorten the time interval from
culture to reporting MRSA, suspected S. aureus isolates
were tested for the presence of coagulase using BD BBL
Coagulase Plasma Rabbit with EDTA (BD, Franklin Lakes,
NJ, USA) (35°C overnight), and plated on oxacillin screen
agar plates containing 6 μg/ml oxacillin and 4% NaCl (BD,
Franklin Lakes, NJ, USA) at 35°C for 24 hours to test for
oxacillin resistance.
Hospital-level infection control practices
Hand hygiene practice continued to improve during the
study period. The increase in hand washing was mea-
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Figure 1 Study design: period one (baseline), period two (intervention period), period three (interruption period) and period four
(re-introduction of intervention period). MRSA: methicillin-resistant Staphylococcus aureus; SICU: surgical intensive care unit.
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period 1, 16.4 liters in period 2, 21.9 liters in period 3
and 23.4 liters in period 4), based on hospital adminis-
trative data.
There was no change in antibiotic prescribing patterns
or overall sepsis management during the study period.
No cohorting was used. Ventilator-associated pneumo-
nia (VAP) bundle care, including head elevation, daily
interruption of sedation for assessing extubation, and
daily 0.2% chlorhexidine mouth cleansing, started in
August 2009.
Individual patient-level risk factors
Data on the severity of underlying diseases, including
Acute Physiology and Chronic Health Evaluation II
(APACHE II) score upon admission to the ICU, length
of hospital stay before ICU admission and invasive pro-
cedures, were routinely recorded. We retrospectively ob-
tained patient-level data from the hospital’s computer
system database. The APACHE II scores were divided
into two groups (low and high), using a cutoff point
of 15 [19].
Outcome ascertainment
In the study hospital, infection control nurses routinely re-
view all hospitalizations for all types of healthcare-
associated infections (HAIs) using the Centers for Disease
Control and Protection (CDC) surveillance definitions
[20,21]. The surveillance practice for detecting the HAIs
remained the same throughout the study period. Data on
HA-MRSA cases that occurred during the study period
were retrospectively obtained from the routine surveil-
lance records. The SICU HA-MRSA infection rate wasdefined as the number of HA-MRSA infections per 1,000
patient SICU days. In-hospital HA-MRSA infection rate
was defined as the number of HA-MRSA infections per
1,000 patient days from the time of SICU admission to
discharge.
The in-hospital mortality of the patients was ascertained
using hospital medical records and death certificates. The
90-day mortality (from SICU admission, including deaths
occurring after discharge) of the patients was ascertained
using the National Death Registry [5], updated to the end
of 2010. To protect the privacy of patients, personal iden-
tification numbers were scrambled and anonymized be-
fore database linkage.Medical cost
Data on length of hospital stay and medical costs were
obtained from the National Health Insurance Claims
database [5] of the study hospital. The list of medical
costs included the costs for physician care, accommoda-
tions, nursing care, pharmacy services, laboratory proce-
dures, operations, rehabilitation programs, medications
and anesthesia.Cost of intervention
All costs were calculated using an exchange rate of
US$1 = NT$30. The costs for active screening included
the cost of the materials for microbiological procedures
(US$5 (NT$150) per ICU patient) and the cost of nurs-
ing personnel (US$6.7 (NT$200)/hour × 5 minutes per
ICU patient) and laboratory technicians (US$5 (NT$150)/
hour × 10 minutes per patient). The cost for decoloniza-
tion included the cost of mupirocin (1 tube at US$1.7
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US$0.19 (NT$5.8), per MRSA carrier).
The costs for contact isolation included the costs of
gloves (US$0.05 (NT$1.6) per unit), surgical masks
(US$0.04 (NT$1.28) per unit), aprons (cleansing and
disinfection) (US$0.003 (NT$0.08) per unit) and alco-
hol disinfectants for hand washing (10 ml at US$0.12
(NT$3.64), after each contact). There were, on average,
fifty contacts per day (including forty nursing contacts,
two physician contacts, four respiratory therapist contacts,
two nursing specialist contacts, and two paramedic con-
tacts), for a total of fourteen days of isolation for each
MRSA carrier. We assumed a 100% adherence to contact
precautions, with gloves, mask and apron changed after
each contact, as well as hand washing.Statistical analyses
All analyses were conducted using SAS version 9.2 (SAS
Institute, Cary, NC, USA). Risk factors for MRSA infec-
tions or mortality were analyzed using logistic regression
or Cox regression. For multivariate analyses, all potential
risk factors were included in the maximum model. We
used stepwise regression procedures to identify independ-
ent risk factors. All tests were two-tailed, and P <0.05 was
considered to be statistically significant.Number of MRSA infections averted
We estimated the number of MRSA infections that
would have occurred in the absence of the intervention
program using the following formula:
Total patient days in period two × (observed MRSA in-
fection rate in period two/adjusted hazard ratio of inter-







Age (mean ± SD) 62 ± 18 65 ± 17
Age >65 (years) 163 (49.8) 177 (56.4)
Male 204 (62.4) 189 (60.1)
Pre-ICU LOS (mean ± SD) 4.1 ± 7.7 5.5 ± 12.4
APACHE II (median) 16 15
APACHE II >15 182 (55.7) 157 (50)
Endotracheal intubation 58 (17.7) 50 (15.9)
Operation 210 (64.2) 229 (72.9)
CVC catheter 164 (50.1) 169 (53.8)
Foley catheter 128 (39.1) 104 (33.1)
Double lumen catheter 11 (3.4) 11 (3.5)
Data are number (%) unless otherwise specified. APACHE II: Acute Physiology and C
ICU length of hospital stay (days).MRSA infection rate in period four/adjusted hazard ratio
of intervention).
The number of MRSA infection cases averted by the
intervention program was estimated using the predicted
numbers (in the absence of the program) in Periods 2
and 4 minus the observed number in Periods 2 and 4.Cost-saving analysis
The cost saved by the intervention was estimated by
multiplying the number of averted MRSA infections with
the median excess total hospitalization for each MRSA in-
fection case. We estimated the cost saved for every dollar
spent on active screening and decolonization program by
dividing the cost saved for the averted MRSA infections
by the cost of implementing the intervention.Results
Baseline characteristics
A total of 2,373 patients were admitted to the SICU
during the study period. Table 1 shows the baseline
characteristics of the patients admitted during the dif-
ferent periods.Active surveillance cultures
Of the 314 patients admitted in period 2, 213 (67.8%) re-
ceived active screening for MRSA. The remaining 101
patients did not receive such surveillance cultures be-
cause of mortality soon after admission or rapid transfer
to other wards. Similarly, of the 833 patients admitted in
period 4, 538 (64.5%) received surveillance cultures. The
average ICU-admission-to-culture-reporting time was
2.5 days. Among surveillance cultures, the positive rated to the surgical ICU







0.060 61 ± 18 62 ± 18 0.234
0.098 424 (52.9) 408 (51.1) 0.450
0.569 543 (60.4) 481 (57.7) 0.261
0.104 3.5 ± 7.4 3.2 ± 6.7 0.310
0.368 10 10 0.263
0.151 271 (30.2) 260 (31.3) 0.630
0.540 124 (13.7) 102 (12.2) 0.340
0.018 680 (75.6) 594 (71.3) 0.036
0.353 451 (50.1) 395 (47.4) 0.253
0.113 300 (33.3) 305 (36.6) 0.157
0.923 36 (4) 27 (3.2) 0.397
hronic Health Evaluation II; CVC: Central venous catheter; Pre-ICU LOS: before
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(33 out of 538), respectively (P = 0.028).Healthcare-associated MRSA infection rates in the
surgical ICU
Twenty-three patients developed MRSA infections (in-
cluding eleven bloodstream infections, eight respiratory
tract infections, two urinary tract infections, one cardio-
vascular system infection and one eye, ear, nose, throat
or mouth infection) during their stay in the SICU in
non-intervention periods, compared with two patients
(two respiratory tract infections) during the intervention
periods (Table 2). After the start of intervention, the
monthly MRSA infection rate in the SICU rapidly
dropped to zero (Figure 2) (overall MRSA infection rate:
3.58‰ (period 1) versus 0.42‰ (period 2), P <0.05).
After the suspension of the program in May 2008, the
monthly MRSA infection rates in the SICU rapidly re-
surged and rose to 12‰ in August 2009 (Figure 2), des-
pite an improved hand hygiene practice from 16.44 to
21.87 liters per 1,000 patient days. After re-introduction
of the intervention program in September 2009, the
monthly MRSA infection rate rapidly dropped to zero
again (Figure 2) (overall MRSA infection rate: 2.21‰
(period 3) versus 0.18‰ (period 4), P <0.05).Effect of intervention on in-hospital MRSA infections
Univariate logistic regression analysis showed that the ac-




Total patient days (SICU) 2,792
Total patient days (in-hospital) 7,028
% of patients screened at ICU admission -
MRSA positive rate of surveillance culture -
MRSA infection rate (‰) (SICU) 3.58





Other infection sites (CVSI, EENTI) 1
MRSA infection rate (‰) (in-hospital) 1.42
In-hospital MRSA infection (number) 10
aBoth cases had negative surveillance culture at the time of SICU admission. bInclud
occurred after transfer to general wards, three cases had negative surveillance cultu
culture at the time of SICU admission. BSI: Bloodstream infection; CVSI: Cardiovascu
Methicillin-resistant Staphylococcus aureus; RTI: Respiratory tract infection; SICU: Surgprotective factor for in-hospital MRSA infections (Table 3).
Multiple logistic regression analysis showed that the inter-
vention was an independent protective factor (adjusted
odds ratio (OR): 0.3; 95% CI: 0.1 to 0.8) (Table 3).
Univariate Cox regression analysis showed that the ac-
tive screening and decolonization program was a signifi-
cant protective factor for MRSA infections (Table 4).
Multiple Cox regression analysis showed that the inter-
vention was an independent protective factor (adjusted
hazard ratio (HR): 0.3; 95% CI: 0.1 to 0.7) (Table 4).In-hospital mortality
The in-hospital mortality rate of patients admitted to
the SICU was 19.3% (63 out of 327) in period 1, which
decreased to 13.7% (43 out of 314) in period 2 (interven-
tion period), increased again to 15.6% (140 out of 899)
in period 3 (interruption period) and decreased again to
13.4% (112 out of 833) in period 4 (re-introduction
period). Patients admitted to the SICU during the inter-
vention periods had a significantly lower in-hospital mor-
tality than those admitted during the non-intervention
periods (13.5% (155 out of 1,147) versus 16.6% (203 out of
1,226); P = 0.038; chi-square test).Effect of intervention on 90-day mortality
Table 5 shows the results of Cox regression analysis
for risk factors of mortality within 90 days. Multiple
Cox regression analysis showed that the intervention
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Figure 2 Monthly incidence of healthcare-associated methicillin-resistant Staphylococcus aureus infections during non-intervention
periods (period one and period three) and intervention periods (period two and period four) in the surgical intensive care unit.
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for the effects of the other variables (Table 5).
Excess length of hospital stay
Mean length of hospital stay was significantly higher for
patients with MRSA infections than for those without
MRSA infections (in SICU: 40.6 days versus 6.6 days;
total hospitalization: 75.4 days versus 23.3 days; bothTable 3 Risk factors for in-hospital MRSA infections
Univariate logistic regression analysis Multiple logistic
regression analysis
Variable OR (95% CI) P value Adjusted OR
(95% CI)
P value
Age >65 (years) 2.1 (0.9-4.7) 0.077
Sex 1.0 (0.5-2.1) 0.961
Pre-ICU LOS 1.0 (1.0-1.1) 0.148
Operation 1.4 (0.5-3.3) 0.513
CVC catheter 1.7 (0.8-3.8) 0.166




APACHE II >15 3.0 (1.4-6.5) 0.007 2.6 (1.1-6.0) 0.025
Endotracheal
intubation
4.3 (2.0-9.4) 0.0001 3.5 (1.6-8.0) 0.002
Antibiotic use 1.4 (0.6-3.1) 0.469
Hand hygienea,b 0.9 (0.8-1.0) 0.029
VAP bundle 0.3 (0.1-0.8) 0.021
Intervention 0.3 (0.1-0.8) 0.009 0.3 (0.1-0.8) 0.015
aHand hygiene: the amount of alcoholic disinfectant (liter) used for hand
washing per 1,000 patient days during a period. bP = 0.569 for the interaction
between intervention and hand hygiene. APACHE II: Acute Physiology and
Chronic Health Evaluation II; CVC: central venous catheter; ICU LOS: ICU length
of hospital stay; OR: odds ratio; MRSA: methicillin-resistant Staphylococcus
aureus; VAP: ventilator-associated pneumonia.P <0.001), with an excess of 34.0 days (in SICU) and
52.1 days (total hospitalization) (Table 6).
Excess cost for patients with MRSA infections
The mean hospital cost was significantly higher for pa-
tients with MRSA infections than for those without
MRSA infections (in SICU: US$25,466 versus US$6,612;
total hospitalization: US$31,815 versus US$8,505; bothTable 4 Risk factors for time to in-hospital MRSA infections
Univariate Cox regression analysis Multiple Cox
regression analysis
Variable HR (95% CI) P value Adjusted HR
(95% CI)
P value
Age >65 (years) 1.5 (0.7-3.4) 0.307
Sex 1.0 (0.5-2.2) 0.972
pre-ICU LOS 1.0 (1.0-1.0) 0.680
Operation 1.1 (0.4-2.6) 0.913
CVC catheter 1.1 (0.5-2.4) 0.858








Antibiotic use 1.2 (0.5-2.8) 0.657
Hand hygienea,b 0.9 (0.8-1.0) 0.051
VAP bundle 0.3 (0.1-0.9) 0.025
Intervention 0.3 (0.1-0.7) 0.010 0.3 (0.1-0.7) 0.006
aHand hygiene: the amount of alcoholic disinfectant (liter) used for hand
washing per 1,000 patient days during a period. bP = 0.597 for the interaction
between intervention and hand hygiene. APACHE II: Acute Physiology and
Chronic Health Evaluation II; CVC: central venous catheter; HR: hazard ratio;
ICU LOS: ICU length of hospital stay; MRSA: methicillin-resistant Staphylococcus
aureus; VAP: ventilator-associated pneumonia.
Table 5 Risk factors for 90-day mortality
Univariate Cox regression analysis Multiple Cox
regression analysis
Variable HR (95% CI) P value Adjusted HR
(95% CI)
P value
Age >65 (years) 2.4 (1.9-2.8) <0.0001 1.5 (1.2-1.8) 0.0002
Sex 1.0 (0.8-1.1) 0.730
pre-ICU LOS 1.0 (1.0-1.0) <0.0001 1.0 (0.99-1.0) 0.421
Operation 0.4 (0.3-0.5) <0.0001 0.3 (0.3-0.4) <0.0001
CVC catheter 1.6 (1.3-1.9) <0.0001 1.5 (1.2-1.9) 0.0002
Foley catheter 2.6 (2.2-3.2) <0.0001 1.4 (1.2-1.7) 0.0007
Double lumen
catheter
4.3 (3.2-5.7) <0.0001 1.7 (1.2-2.3) 0.001
APACHE II >15 3.8 (3.1-4.5) <0.0001 2.5 (2.0-3.0) <0.0001
Endotracheal
intubation
3.8 (3.1-4.5) <0.0001 1.5 (1.2-1.9) 0.0003
Hand hygienea,b 0.95 (0.9-0.98) 0.002 1.0 (0.9-1.0) 0.617
Intervention 0.9 (0.7-1.1) 0.219 0.8 (0.7-0.99) 0.048
aHand hygiene: the amount of alcoholic disinfectant (liter) used for hand
washing per 1,000 patient days during a period. bP = 0.16 for the interaction
between intervention and hand hygiene. APACHE II: Acute Physiology and
Chronic Health Evaluation II; CVC: central venous catheter; HR: hazard ratio;
ICU LOS: ICU length of hospital stay.
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US$23,310 (total hospitalization) (Table 6).
Cost-saving by intervention
The number of MRSA cases prevented by the interven-
tion was estimated to be 13 (6,817 patient days (periodTable 6 Comparison of hospital stay and hospital cost for








Length of stay (days)
SICU length of stay (mean) 40.6 6.6 <0.001
SICU length of stay (median) 37 2 <0.001
Total length of hospital
stay (mean)
75.4 23.3 <0.001




SICU costs (mean) 25,466 6,612 <0.001







ain US dollars (exchange ratio US$1 = NT$30). bThe medical cost, including
physician care, accommodation, nursing care, meals, laboratory procedures,
treatments, operations, rehabilitation programs, medications, pharmacy service
and anesthesia. MRSA: methicillin-resistant Staphylococcus aureus; SICU: surgical
intensive care unit.2) × 0.00029 (observed MRSA infection rate in period
2)/0.3 (adjusted HR of intervention) + 16,523 patient
days (period 4) × 0.00024 (observed MRSA infection rate
in period 4)/0.3 (adjusted HR of intervention)).
The cost saved by preventing 13 MRSA cases during
the total 20-month intervention period (periods 2 and 4)
was 13 × US$23,310 = US$303,030 (annual cost saving:
US$190,908). The active surveillance and decolonization
program cost US$13,717 during the total 20-month
intervention period (annual cost: US$8,231). The cost-
saving ratio was 22 (US$303,030/US$13,717); thus, every
dollar spent on the intervention resulted in a saving of
$22 in medical costs.
Discussion
Our results show that the active screening and de-
colonization program was associated with a decrease in
all-type clinical in-hospital MRSA infections (adjusted
OR: 0.3; 95% CI: 0.1 to 0.8) and a lower 90-day mortality
(adjusted HR: 0.8; 95% CI: 0.7 to 0.99). Furthermore, the
active screening and decolonization program is cost-
saving; every dollar spent on interventions resulted in a
saving of $22 in medical costs.
Due to ethical considerations, we were unable to use
randomized controlled experiments to evaluate the
active screening and decolonization program. Neverthe-
less, the interrupted time-series study design, in con-
junction with the use of regression models to control
the effects of hospital-level and patient-level con-
founders, strengthens the causal inference. The rapid
drop, resurgence and drop again in MRSA infection
rates, following introduction, interruption and re-
introduction of the interventions in temporal sequence,
makes a strong case against alternative explanations
such as a progressive decline in MRSA carrier rates in
community, or a continuing improvement in overall
hospital infection control measures. Furthermore, after
adjusting for effects of hospital-level improvements in
infection-control practices (hand hygiene and bundle
care), as well as individual patient-level risk factors (in-
vasive procedures and severity of underlying diseases),
the intervention remains an independent protective fac-
tor against MRSA infection and mortality.
The protective effect measured in our study includes
both the direct effect and the indirect effect. Decoloniza-
tion of MRSA carriers directly reduces his or her risk of
subsequent MRSA infections. Moreover, decolonization
of MRSA carriers prevents the transmission of MRSA to
non-carriers that would otherwise happen, and therefore
indirectly protects those who are not carriers at the time
of ICU admission.
The impact of active screening and decolonization on
MRSA transmission within hospitals is further high-
lighted by a decrease in the prevalence of MRSA carriers
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studies predict that, in settings where MRSA carriage is
endemic, the implementation of active screening and
decolonization will lead to a rapid drop in MRSA carriage
rate in hospitalized patients [22]. As predicted by model-
ing studies, the average MRSA-positive rate among sur-
veillance cultures in our study rapidly dropped from the
initial 11.3% (24 out of 213; period 2) to 6.1% (33 out of
538; period 4) (P = 0.038). The 47% decrease in MRSA
carriage rate (from 11.3 to 6.1%) within a short time
period is consistent with the effect of the active screening
and decolonization program in period 2 on blocking noso-
comial MRSA transmission [22].
The use of intranasal mupirocin and chlorhexidine
baths for decolonization in our study is likely the key
factor of the observed efficacy. Two recent cluster-
randomized trials conclusively showed that active sur-
veillance and isolation alone, in the absence of a
decolonization program, did not reduce the MRSA-
positive clinical culture rate or the MRSA bloodstream
infection rate [13,23,24]. Although another study re-
ported that universal surveillance, contact precaution
and hand hygiene without decolonization were associ-
ated with a 62% decrease in MRSA infections in ICUs
[25], an independent analysis of the data using math-
ematical modeling showed that only a very small frac-
tion of the observed effect could be attributed to active
detection and isolation alone [26].
MRSA infections increase the mortality of hospitalized
patients by 12.4 to 28.5% [5]. Theoretically, prevention
of HA-MRSA infections in ICU patients should lead to a
reduction in mortality. However, the survival of ICU pa-
tients is heavily influenced by their acute severity of ill-
nesses, prior length of stay and underlying diseases
[19,27], which need to be taken into account in analyz-
ing the effect of interventions on the mortality of ICU
patients. We showed that, after adjusting for effects of
the above-stated variables, the active screening and
decolonization program is an independent protective
factor against mortality. Thus, decolonization of MRSA
is not only an infection-control measure, but also could
be a potentially life-saving intervention for all ICU pa-
tients in settings with a high MRSA infection rate.
In the present study, we used inexpensive conventional
screening plates to detect MRSA carriers, with a turn-
around time of two to three days. The efficacy of inter-
ventions may be better if rapid tests were used for
screening to minimize the delay in initiating decoloniza-
tion. Tests based on real-time PCR have a turnaround
time of less than one day, but are expensive [28].
Culture-based methods using chromogenic screening
media can yield a rapid result after 18 to 24 hours incu-
bation, but sensitivity varies by product, and is usually
lower than that of PCR-based methods [29].Because of logistic consideration, we did not obtain
extra-nasal cultures when screening individuals for MRSA
colonization. Use of nasal culture to guide decolonization
in our study, however, appears to be sufficient to yield a
significant decrease in MRSA infection rates and decrease
in mortality. The additional use of extra-nasal cultures will
likely detect more MRSA carriers, and thus increase the
impact of the intervention [30].
Cost is an important concern for the sustained imple-
mentation of HAI prevention efforts. Consistent with
previous cost analyses of MRSA prevention programs
[31-33], our data show that, because of the high excess
cost associated with MRSA infection and related compli-
cations (US$23,310 per MRSA infection case) in the
SICU setting, the investment in active screening and
decolonization (US$8,231 per year) will actually be cost-
saving if at least one case of MRSA infection is pre-
vented in the SICU every year. We estimated that 13
cases of MRSA infections had been prevented during
the total 20-month intervention period, which yielded a
highly beneficial cost-saving ratio of 22.
An alternative to the screening followed by targeted
decolonization approach is universal decolonization for all
ICU patients [12,34]. A multicenter cluster-randomized
trial showed that daily chlorhexidine baths for all ICU pa-
tients reduced hospital-acquired bloodstream infection
rates by 28% [34]. The REDUCE MRSA trial further dem-
onstrated that universal administration of intranasal
mupirocin and daily chlorhexidine baths in ICUs was
more effective at reducing the MRSA clinical culture rate
and bloodstream infection rate from any pathogen than
was targeted decolonization [12]. Universal decolonization
eliminates the problem of false negative screening results.
There will be no delay in initiating decolonization [12].
Additional advantages include reduction in contact pre-
caution, as well as reduction in infections caused by bac-
teria other than MRSA [12]. It is reasonable to expect that
universal decolonization will have a greater effect in redu-
cing mortality of ICU patients than targeted decoloniza-
tion. However, an important concern for the universal use
of mupirocin for all ICU patients is selection for
mupirocin-resistant strains [24,35]. Moreover, for those
ICU patients who do not carry MRSA, the use of mupiro-
cin is arguably not justified. Until these concerns can be
adequately addressed, targeted decolonization remains an
important option for reducing MRSA-related morbidity
and mortality in routine clinical settings.
Our study has several limitations. First, our results in
the SICU may not be generalizable to medical ICUs,
where patients generally have prolonged hospital stays
and more complicated illnesses than patients in SICUs.
Second, we did not conduct a molecular analysis of the
MRSA strains isolated during the study periods to differ-
entiate MRSA of endogenous origin from MRSA that
Lee et al. Critical Care  (2015) 19:143 Page 9 of 10was exogenously acquired through intra-hospital trans-
mission. Additional limitations included the lack of
follow-up cultures during the study period; thus, the ef-
fect of the mupirocin eradication of the MRSA in the
carriers was not documented. Further monitoring of
MRSA susceptibility to mupirocin is necessary to ensure
the long-term efficacy of the program.
Conclusions
Active screening for MRSA and decolonization in ICU
settings with a high MRSA infection rate is associated
with a decrease in MRSA infections, mortality and med-
ical cost.
Key messages
 Methicillin-resistant Staphylococcus aureus (MRSA)
is a leading pathogen of healthcare-associated
infections in intensive care units (ICUs).
 Routine active screening for MRSA and
decolonization in ICU settings is associated with a
decrease in MRSA infections, mortality and medical
cost in settings with a high MRSA infection rate.
 Both MRSA carriers and non-carriers can benefit
from a routine active MRSA screening and
decolonization program.
 In settings where MRSA is endemic, MRSA carriage
rate drops after implementation of the active
screening and decolonization program.
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